The global PARP inhibitor market, valued at USD 7.4 billion in 2026, is projected to reach USD 17.1 billion by 2036, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period. This growth reflects the increasing role of PARP inhibitors in treating cancers such as ovarian, breast, prostate, and pancreatic cancer by targeting DNA repair mechanisms in tumor cells, according...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek